WNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma.

MLA

“WNT/β-Catenin Signaling and CD8+ Tumor-Infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma.” In Vivo, vol. 38, no. 6, Nov. 2024, pp. 2774–81. EBSCOhost, https://doi.org/10.21873/invivo.13757.

APA

WNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma. (2024). In Vivo, 38(6), 2774–2781. https://doi.org/10.21873/invivo.13757

Chicago

“WNT/β-Catenin Signaling and CD8+ Tumor-Infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma.” 2024. In Vivo 38 (6): 2774–81. doi:10.21873/invivo.13757.